The Clinical Development of Taldefgrobep Alfa: An Anti-Myostatin Adnectin for the Treatment of Duchenne Muscular DystrophyFrancesco Muntoni, Alberto Dubrovsky, Barry J. Byrne et al.|Neurology and Therapy|2024Cited by 23
AB0609 DESIGN OF A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, GLOBAL TRIAL OF DEUCRAVACITINIB, AN ORAL, SELECTIVE, ALLOSTERIC TYROSINE KINASE 2 (TYK2) INHIBITOR, IN PATIENTS WITH ACTIVE DISCOID AND/OR SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUSVictoria P. Werth, Shimon Korish, Joseph F. Merola et al.|Unknown|2023Cited by 0
LP-180 Design of a phase 2, double-blind, placebo-controlled, global trial of deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in patients with active discoid and/or subacute cutaneous lupus erythematosusVictoria P. Werth, Shimon Korish, Shalabh Singhal et al.|Unknown|2023Cited by 0